

Dear Editor,

I have read the comments of the reviewers regarding my manuscript "Checkpoint inhibitors: what Gastroenterologists need to know". My responses are as follows:

Reviewer Number ID. : 03551817

1. The newer checkpoints TIM3, LAG3, TIGIT and BTLA have been discussed.
2. I have discussed PD-1, PD-L1 and CTLA-4 as they are the initial checkpoints discovered and monoclonal antibodies against them are commercially available.
3. The mechanism of action of checkpoint inhibitors have been further elaborated.
4. Use of combination of checkpoint inhibitors has been mentioned.

Reviewer Number ID: 00504187

1. The review is mainly addressed to gastroenterologists
2. The differential diagnosis of side effects and different degrees of severity of diarrhea are mentioned in a nut shell
3. The English language has been revised.
4. Mechanism of action of drugs has been written simpler.

Reviewer Number ID: 00058401

Minor language polishing has been done.

Reviewer Number ID: 03004570

1. The indications of checkpoint inhibitors have been revised .
2. The current references have been given.
3. The mechanism of CTLA-4 has been revised.
4. Figure 1 has been refreshed and redrawn.

Reviewer Number ID: 01851506

1. The jargons lab, Rx and IV have been eliminated.
2. The grammatical and typographical errors have been corrected.

Reviewer Number ID: 00070916

1. The quality of English language has been improved by full revision.
2. Mechanism of checkpoint inhibition has been revised.
3. Great success of treatment of hyperstimulated colon cancer has been mentioned.
4. Conclusion has been modified.
5. In key words, clinical management of side effects has been mentioned.